Physician profile
David Robertson
NPI 1326195215
$58,173.64
in general payments reported to CMS, 2019-2025
17 companies · $28K in 2025
The $28K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $18K · 2021: $94.50 · 2022: $113 · 2023: $162 · 2024: $747 · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Food and Beverage: $1,075 · Travel and Lodging: $609 · Education: $457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,332.00 |
| Food and Beverage | $1,074.72 |
| Travel and Lodging | $609.39 |
| Education | $457.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $28,882.47 | 2019-2020 | |
| Emd Serono, INC. | $27,623.67 | 2020-2025 | Mavenclad, Mavenclad |
| Alexion Pharmaceuticals, INC. | $581.99 | 2019-2024 | Ultomiris, Soliris |
| E.R. Squibb & Sons, L.L.C. | $207.38 | 2021-2022 | |
| Genzyme Corporation | $163.16 | 2019 | |
| Tg Therapeutics, INC. | $144.46 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $139.61 | 2019-2024 | |
| Depuy Synthes Sales INC. | $122.50 | 2024 | Embotrap |
| Sk Life Science, INC. | $85.91 | 2024 | |
| Genentech USA, INC. | $52.82 | 2019-2025 | Ocrevus Zunovo |
| Supernus Pharmaceuticals, INC. | $31.57 | 2019 | |
| Celgene Corporation | $30.42 | 2023-2025 | Zeposia |
| Mdd US Operations, LLC | $28.41 | 2019 | |
| Abbvie INC. | $21.52 | 2025 | |
| Chiesi USA, INC. | $21.16 | 2025 | Myalept |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $20.81 | 2024 | Sogroya |
| Vanda Pharmaceuticals INC. | $15.78 | 2025 | Ponvory |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Robertson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.